Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Prepaid Assets: 2020-2025

Historic Prepaid Assets for Caribou Biosciences (CRBU) over the last 5 years, with Sep 2025 value amounting to $5.3 million.

  • Caribou Biosciences' Prepaid Assets fell 19.23% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year decrease of 19.23%. This contributed to the annual value of $6.6 million for FY2024, which is 7.05% up from last year.
  • Per Caribou Biosciences' latest filing, its Prepaid Assets stood at $5.3 million for Q3 2025, which was down 7.98% from $5.8 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Prepaid Assets registered a high of $8.6 million during Q3 2022, and its lowest value of $5.0 million during Q2 2021.
  • Over the past 3 years, Caribou Biosciences' median Prepaid Assets value was $6.2 million (recorded in 2023), while the average stood at $6.2 million.
  • Its Prepaid Assets has fluctuated over the past 5 years, first soared by 126.62% in 2021, then dropped by 25.87% in 2023.
  • Over the past 5 years, Caribou Biosciences' Prepaid Assets (Quarterly) stood at $7.2 million in 2021, then increased by 9.47% to $7.9 million in 2022, then dropped by 22.30% to $6.2 million in 2023, then climbed by 7.05% to $6.6 million in 2024, then fell by 19.23% to $5.3 million in 2025.
  • Its Prepaid Assets was $5.3 million in Q3 2025, compared to $5.8 million in Q2 2025 and $6.1 million in Q1 2025.